Benign versus destructive insulitis

Diabetes/Metabolism Reviews

Volumn 13, Issue 3, 1997, Pages 139-146

  Kolb, Hubert ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANIMAL CELL; ANIMAL MODEL; AUTOIMMUNITY; CONTROLLED STUDY; HELPER CELL; HUMAN; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; T-LYMPHOCYTES;

ANIMALIA;

EID: 0030984434     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199709)13:3<139::AID-DMR190>3.0.CO;2-9     Document Type: Review

References (96)

1. Zielasek J, Jackson RA, and Eisenbarth GS: The potentially simple mathematics of type I diabetes. Clin Immunol Immunopathol 52: 347-365, 1989.
2. McCulloch DK, Klaff LJ, Kahn SE, Schoenfeld SL, Greenbaum CJ, Mauseth RS, Benson EA, Nepom GT, Shewey L, and Palmer GP: Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients: 5-yr follow-up of the Seattle Family Study. Diabetes 39: 549-556, 1990.
3. Bingley PJ, Bonifacio E, Shattock M, Gillmor HA, Sawtell PA, Dunger DB, Scott RDM, Bottazzo GF, and Gale EAM: Can islet cell antibodies predict IDDM in the general population? Diabetes Care 16: 45-50, 1993.
4. Verge CF, Gianani R, Pietropaolo M, Smith T, Jackson RA, Soeldner JS, and Eisenbarth GS: Late progression to diabetes and evidence for chronic beta-cell autoimmunity in identical twins of patients with type 1 diabetes. Diabetes 44: 1176-1179, 1995.
5. Pugliese A, Gianani R, Moromisato R, Awdeh ZL, Alper CA, Erlich HA, Jackson RA, and Eisenbarth GS: HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 44: 608-613, 1995.
6. Nakhooda AF, Like AA, Chappel CL, Murray FT, and Marliss EB: The spontaneously diabetic Wistar rat: Metabolic and morphologic studies. Diabetes 26: 100-112, 1977.
7. Lampeter EF, Signore A, Gale EAM, and Pozzilli P: Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type I (insulin dependent) diabetes mellitus. Diabetologia 32: 703-708, 1989.
8. Leiter EH, Prochazka M, and Coleman DL: Animal model of human disease: the non-obese diabetic (NOD) mouse. Am J Pathol 128: 380-391, 1987.
9. Kolb H, Freytag G, Kiesel U, and Kolb-Bachofen V: Spontaneous autoimmune reactions against pancreatic islets in mouse strains with generalized autoimmune disease. Diabetologia 19: 216-221, 1980.
10. Flohr K, Kiesel U, Freytag G, and Kolb H: Insulitis as a consequence of immune dysregulation: Further evidence. Clin Exp Immunol 53: 605-613, 1983.
11. Lampeter EF, Tubes M, Klemens C, Brocker U, Friemann J, Kolb-Bachofen V, Gries FA, and Kolb H: Insulitis and islet-cell antibody formation in rats with experimentally reduced beta-cell mass. Diabetologia 38: 1397-1404, 1995.
12. Wrede G, Kiesel U, Freytag G, and Kolb H: Chronic insulitis after partial islet damage by passive insulin antibody transfer. Horm Metab Res 16 (Suppl.): 97-101, 1984.
13. Grodsky GM, Feldman R, Toreson WE, and Lee JC: Diabetes mellitus in rabbits immunized with insulin. Diabetes 15: 579-585, 1966.
14. Kromann H, Lernmark A, Vestergaard BF, Egeberg J, and Nerup J: The influence of the major histocompatibility complex (H-2) on experimental diabetes in mice. Diabetologia 16: 107-114, 1979.
15. Allison J, Malcolm L, Chosich N, and Miller JFAP: Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of interleukin-2 in islet beta cells. Eur J Immunol 22: 1115-1121, 1992.
16. Higuchi Y, Herrera P, Muniesa P, Huarte J, Belin D, Ohashi P, Aichele P, Orci L, Vassalli J-D, and Vassalli P: Expression of a tumor necrosis factor alpha transgene in murine pancreatic beta cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med 176: 1719-1731, 1992.
17. Picarella DE, Kratz A, Li C-B, Ruddle NH, and Flavella RA: Insulitis in transgenic mice expressing tumor necrosis factor beta (lymphotoxin) in the pancreas. Proc Natl Acad Sci USA 89: 10036-10040, 1992.
18. Picarella DE, Kratz A, Li C-B, Ruddle NH, and Flavell RA: Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. J Immunol 150: 4136-4150, 1993.
19. Allison J, Oxbrow L, and Miller JFAP: Consequence of in situ production of IL-2 for islet cell death. Int Immunol 6: 541-549, 1994.
20. Dicosmo BF, Picarella D, and Flavell RA: Local production of human IL-6 promotes insulitis but retards the onset of insulin-dependent diabetes mellitus in non-obese diabetic mice. Int Immunol 6: 1829-1837, 1994.
21. Vonherrath MG, Allison J, Miller JFAP, and Oldstone MBA: Focal expression of interleukin-2 does not break unresponsiveness to "self" (viral) antigen expressed in beta cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response. J Clin Invest 95: 477-485, 1995.
22. Holers VM, Hollis GF, Schwartz BD, Evans RJ, Strauss-Schoenberger J, Carel J-C, Barney DL, Li B, Stafford-Hollis J, and Lacy PE: Induction of per-insulitis but not diabetes in islet transplants expressing a single foreign antigen. J Immunol 151: 5041-5052, 1993.
23. Martin L, Mora-Worms M, Lucas C, Reynolds C, and Stewart TA: An evaluation of mechanisms by which tolerance to organ-specific antigens is lost using a transgenic mouse model. J Immunol 150: 1234-1243, 1993.
24. Scott B, Liblau R, Degermann S, Marconi LA, Ogata L, Caton AJ, Mcdevitt HO, and Lo D: A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1: 73-82, 1994.
25. Barrett SP, van Driel IR, Tan S-S, Alderuccio F, Toh B-H, and Gleeson PA: Expression of a gastric autoantigen in pancreatic islets results in non-destructive insulitis after neonatal thymectomy. Eur J Immunol 25: 2686-2694, 1995.
26. Shedadeh NN, LaRosa F, and Lafferty KJ: Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmun 6: 291-300, 1993.
27. Sadelain MWJ, Qiun H-Y, Lauzon J, and Singh B: Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39: 583-589, 1990.
28. Uleato D, Lacy PE, Kipnis DM, Kanagawa O, and Unanue ER: A T-cell dormant state in the autoimmune process of nonobese diabetic mice treated with complete Freund's adjuvant. Proc Natl Acad Sci USA 89: 3927-3931, 1992.
29. Rothe H, Faust A, Schade U, Kleemann R, Boose G, Hibino T, Martin S, and Kolb H: Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia 37: 1154-1158, 1994.
30. Shimada A, Charlton B, Taylor-Edwards C, and Fathman CG: Beta-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 45: 1063-1067, 1996.
31. Anderson JT, Cornelius JG, Jarpe AJ, Winter WE, and Peck AB: Insulin-dependent diabetes in the NOD mouse model. II. Beta cell destruction in autoimmune diabetes is a Th2 and not a Th1 mediated event. Autoimmunity 15: 113-122, 1993.
32. Pilstrom B, Bjork L, and Bohme J: Demonstration of a TH1 cytokine profile in the late phase of NOD insulitis. Cytokine 7: 806-814, 1995.
33. Campbell IL, Kay TWH, Oxbrow L, and Harrison LC: Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 87: 739-742, 1991.
34. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, Cyopick P, Danska JS, and Delovitch TL: Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 178: 87-99, 1993.
35. Pennline KJ, Roque-Gaffney E, and Monahan M: Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 71: 169-175, 1994.
36. Allison J, McClive P, Oxbrow L, Baxter A, Morahan G, and Miller JFAP: Genetic requirements for acceleration of diabetes in non-obese diabetic mice expressing interleukin-2 in islet beta-cells. Eur J Immunol 24: 2535-2541, 1994.
37. Rabinovitch A, Sorensen O, Suarez-Pinzon WL, Power RF, Rajotte RV, and Bleackley RC: Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival. Diabetologia 37: 833-837, 1994.
38. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, and Power RF: IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immunol 154: 4874-4882, 1995.
39. low CD4+ cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Diabetes 45: 71-78, 1996.
40. Suarez-Pinzon W, Rajotte RV, Mosmann TR, and Rabinovitch A: Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction. Diabetes 45: 1350-1357, 1996.
41. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, and Bleackley RC: Inducible nitric oxide synthase (iNOS) in pancreatic islet of nonobese diabetic mice: Identification of iNOS-expressing cells and relationship to cytokines in the islets. Endocrinology 137: 2093-2099, 1996.
42. Kolb H, Wörz-Pagenstert U, Kleemann R, Rothe H, Rowsell P, and Scott FW: Cytokine gene expression in the BB rat pancreas: Natural course and impact of bacterial vaccines. Diabetologia 39: 1448-1454, 1996.
43. Zipris D, Greiner DL, Malkani S, Whalen B, Mordes JP, and Rossini AA: Cytokine gene expression in islets and thyroids of BB rats. J Immunol 156: 1315-1321, 1996.
44. Rabinovitch A, Suarez-Pinzon W, El-Sheikh A, Sorensen O, and Power RF: Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: Expression of Th1 cytokines correlates with beta-cell destructive insulitis and IDDM. Diabetes 45: 749-754, 1996.
45. Kay TWH, Campbell IL, Oxbrow L, and Harrison LC: Overexpression of class I major histocompatibility complex accompanies insulitis in the nonobese diabetic mouse and is prevented by antiinterferon-gamma antibody. Diabetologia 34: 779-785, 1991.
46. Debray-Sachs M, Carnaud C, Boitard C, Cohen H, Gresser I, Bedossa P, and Bach J-F: Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun 4: 237-248, 1991.
47. Rabinovitch A: Perspectives in diabetes: Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: therapeutic intervention by immunostimulation? Diabetes 43: 613-621, 1994.
48. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, Power RF, and Rajotte RV: Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice: Analysis of cytokine mRNA expression in the graft. Transplantation 60: 368-374, 1995.
49. Moritani M, Yoshimoto K, Li S, Kondo M, Iwahana H, Yamaoka T, Sano T, Nakano N, Kikutani H, and Itakura M: Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. J Clin Invest 98: 1851-1859, 1996.
50. Mueller R, Krahl T, and Sarvetnick N: Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 184: 1093-1099, 1996.
51. Faust A, Rothe H, Schade U, Lampeter EF, and Kolb H: Primary nonfunction of islet grafts in autoimmune diabetic NOD mice is prevented by treatment with IL-4 and IL-10. Transplantation 62: 648-652, 1996.
52. Rothe H, Burkart V, Faust A, and Kolb H: Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in nonobese diabetic mice. Diabetologia 39: 119-122, 1996.
53. Rothe H, Jenkins NA, Copeland NG, and Kolb H: Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. J Clin Invest 99: 469-474, 1997.
54. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, and Adorini L: Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181: 817-821, 1995.
55. O'Hara RM, Henderson SL, and Nagelin AM: Prevention of a Th1 disease by a Th1 cytokine: Il-12 and diabetes in NOD mice. In IL-12: Cellular and Molecular Immunology of an Important Regulatory Cytokine, Lotze MT, Trinchieri G, Gately M, and Wolf S, Eds. 1997, pp. 241-250.
56. Ziegler-Heitbrock, HWL: Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm 45: 13-26, 1995.
57. Trembleau S, Penna G, Gregori S et al. The role of endogenous IL-12 in the development of spontaneous diabetes in NOD mice. [Abstract] Autoimmunity 21: A 087, 1996.
58. Rothe H, Hibino T, Ito Y, Kolb H, and Martin S: Systemic production of interferon gamma inducing factor (IGIF) versus local IFN-gamma expression involved in the development of Th1 insulitis in NOD mice. J Autoimmunity in press, 1997.
59. Burkart V, and Kolb H: Macrophages in islet destruction in autoimmune diabetes mellitus. Immunobiol 195: 601-613, 1996.
60. Oschilewski U, Kiesel U, and Kolb H: Silica administration prevents diabetes in BB-rats. Diabetes 34: 197-199, 1985.
61. Kolb-Bachofen V, Epstein S, Kiesel U, and Kolb H: Low-dose streptozotocin-induced diabetes in mice: Electron microscopy reveals single cell insulitis before diabetes onset. Diabetes 37: 21-27, 1988.
62. Hanenberg H, Kolb-Bachofen V, Kantwerk-Funke G, and Kolb H: Macrophage infiltration precedes and is a prerequisite for lymphocytic insulitis in pancreatic islets of prediabetic BB rats. Diabetologia 32: 126-134, 1989.
63. Lee K-U, Amano K, and Yoon J-W: Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes 37: 989-991, 1988.
64. Hutchings P, Rosen H, O'Reilly L, Simpson E, Gordon S, and Cooke A: Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature 348: 639-642, 1990.
65. Kolb-Bachofen V, and Kolb H: A role for macrophages in the pathogenesis of type I diabetes. Autoimmunity 3: 145-155, 1989.
66. Serreze DV: Autoimmune diabetes results from genetic defects manifest by antigen presenting cells. FASEB J 7: 1092-1096, 1993.
67. Rothe H, Fehsel K, and Kolb H: Tumour necrosis factor alpha production is upregulated in diabetes prone BB rats. Diabetologia 33: 573-575, 1990.
68. Ridge JP, Fuchs EJ, and Matzinger, P: Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells. Science 271: 1723-1728, 1996.
69. Forsthuber T, Yip HC, and Lehmann PV: Induction of TH1 and TH2 immunity in neonatal mice. Science 271: 1728-1730, 1996.
70. Fearon DT, and Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 272: 50-53, 1996.
71. Pfeiffer C, Stein J, Southwood S, Ketalaar H, Sette A, and Bottomly K: Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 181: 1569-1574, 1995.
72. Satoh J, Seino H, Abo T, Tanaka S-I, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T, Kumagai K, and Toyota T: Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 84: 1345-1348, 1989.
73. Serreze DV, Hamaguchi K, and Leiter EH: Immunostimulation circumvents diabetes in NOD/Lt mice. J Autoimmun 2: 759-776, 1989.
74. Jacob CO, Aiso S, Michie SA, Medevitt HO, and Acha-Orbea H: Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): Similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci USA 87: 968-972, 1990.
75. Campell IL, Oxbrow L, and Harrison LC: Reduction in insulitis following administration of IFN-gamma and TNF-alpha in the NOD mouse. J Autoimmun 4: 249-262, 1991.
76. Formby B, Jacobs C, Dubuc P, and Shao T: Exogenous administration of IL-1 alpha inhibits active and adoptive transfer autoimmune diabetes in NOD mice. Autoimmunity 12: 21-27, 1992.
77. Seino H, Takahashi K, Satoh J, Zhu XP, Sagara M, Masuda T, Nobunaga T, Funahashi I, Kajikawa T, and Toyota T: Prevention of autoimmune diabetes with lymphotoxin in NOD mice. Diabetes 42: 398-404, 1993.
78. Hultgren B, Huang X, Dybdal N, and Stewart TA: Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 45: 812-817, 1996.
79. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA, and Flavell RA: Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 184: 1963-1974, 1996.
80. Wogensen L, Lee M-S, and Sarvetnick N: Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice. J Exp Med 179: 1379-1384, 1994.
81. Moritani M, Yoshimoto K, Tashiro F, Hashimoto C, Miyazaki J, Li S, Kudo E, Iwahana H, Hayashi Y, Sano T, and Itakura M: Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic, Int Immunol 6: 1927-1936, 1994.
82. Lee M-S, Mueller R, Wicker LS, Peterson LB, and Sarvetnick N: IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 183: 2663-2668, 1996.
83. Yang X-D, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, and Mcdevitt HO: Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 180: 995-1004, 1994.
84. Takahashi K, Satoh J, Sagara M, Zhi XP, Muto G, Fukuzawa M, Nishimura S, Miyaguchi S, and Toyota T: Analysis of action mechanism of lymphotoxin in prevention of cyclophosphamide-induced diabetes in NOD mice. J Autoimmun 8: 335-346, 1995.
85. Sarvetnick N: Mechanisms of cytokine-mediated localized immunoprotection. J Exp Med 184: 1597-1600, 1996.
86. Pasparakis M, Alexopoulou L, Episkopou, V, and Kollias G: Immune and inflammatory response in TNF alpha-deficient mice: A Critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184: 1397-1411, 1996.
87. Barnes PJ, and Liew FY: Nitric oxide and asthmatic inflammation. Immunol Today 16: 128-130, 1995.
88. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, and Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J Immunol 157: 1261-1270, 1996.
89. Lundberg JON, Lundberg JM, Alving K, and Weitzberg E: Nitric oxide and inflammation: The answer is blowing in the wind. Nature Med 3: 30-31, 1997.
90. Graziosi C, Pantaleo G, Gantt KR, Fortin J-P, Demarest JF, Cohen OJ, Sekaly RP, and Fauci AS: Lack of evidence for dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 265: 248-252, 1994.
91. Niessner M, and Volk BA: Altered Th1/Th2 cyrokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101: 428-435, 1995.
92. Nilson EM, Gjertsen HA, Jensen K, Brandtzaeg P, and Lundin KEA: Gluten activation of peripheral blood T cells induces a Th0-like cytokine pattern in both coeliac patients and controls. Clin Exp Immunol 103: 295-303, 1996.
93. Renz H, Gong JH, Nain M, and Gemsa D: Release of TNF-alpha from macrophages: Enhancement and suppression are dose-dependently regulated by prostaglandine E2 and cyclic nucleotides. J Immunol 141: 2388-2395, 1988.
94. Appels B, Burkart V, Kantwerk-Funke G, Funda J, Kolb-Bachofen V, and Kolb H: Spontaneous cytotoxicity of macrophages against pancreatic islet cells. J Immunol 142: 3803-3808, 1989.
95. Steiner L, Kröncke K-D, Fehsel K, and Kolb-Bachofen V: Endothelial cells as cytotoxic effector cells: Cytokine-activated rat islet endothelial cells lyse syngeneic islet cells via nitric oxide. Diabetologia 40: 150-155, 1997.
96. Nagata M, Yokono K, Hayakawa M, Kawase Y, Hatamori N, Ogawa W, Yonezawa K, Shii K, and Baba S: Destruction of pancreatic islet cells by cytotoxic T lymphocytes in nonobese diabetic mice. J Immunol 143: 1155-1162, 1989.